CAR-T Meeting 2026 | The launch of the T2EVOLVE Association: driving innovation in cellular therapy across Europe
In this interview, Carmen Sanges, PhD, University Hospital Würzburg, Würzburg, Germany, discusses the transition of the T2EVOLVE consortium into a pan-European association. The association aims to foster collaboration across European cellular therapy initiatives, with the core mission of driving innovation and increasing access to cellular therapies across Europe. This interview took place at the EBMT-EHA 8th European CAR T-cell Meeting, held in Palma de Mallorca, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The T2EVOLVE Consortium actually ended in December 2025, and now we have transitioned into an association. We are a registered Verein, because we are based in Germany, but we are a pan-European association that is looking into overarching, centralizing, integrating, and transforming and amplifying all the European initiatives around the cell-based therapies. Of course, our core mission is to increase the access of the CAR and TCR therapies across Europe, but we will go beyond that and we will really embrace all the cell therapies...
The T2EVOLVE Consortium actually ended in December 2025, and now we have transitioned into an association. We are a registered Verein, because we are based in Germany, but we are a pan-European association that is looking into overarching, centralizing, integrating, and transforming and amplifying all the European initiatives around the cell-based therapies. Of course, our core mission is to increase the access of the CAR and TCR therapies across Europe, but we will go beyond that and we will really embrace all the cell therapies. Also, we will go beyond the commercial application of the CAR technology and we will embrace the community of autoimmune diseases, for example, or the infectious diseases and all the applications and domains that are actually already proving their potential in therapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
